Global Respiratory Market 1993-2000
Worldwide, the respiratory drugs market was worth $8.6 billion in 1993, and accounted for almost 6% of the world pharmaceutical market, according to a new report from Datamonitor (priced at $1,450 and available through the Marketletter).
The report notes that the largest segment of the respiratory market is the asthma drug segment, consisting of bronchodilators and anti-inflammatories. These two therapy areas have a market share of 55%, followed by non-asthma allergy products, with sales of $3 billion, having a 36% share. Antitussives have a 6% share.
The top selling drug in the sector is Glaxo's Ventolin (salbutamol), with product sales of $722 million and market share of 8.4%, while Marion Merrell Dow's Seldane (terfenadine) continues to lose market share, as sales declined by $115 million to $605 million, and a 7.0% market share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze